158 related articles for article (PubMed ID: 18650174)
1. An international, multicenter, randomized phase III study of first-line erlotinib followed by second-line cisplatin/gemcitabine versus first-line cisplatin/gemcitabine followed by second-line erlotinib in advanced non-small-cell lung cancer: treatment rationale and protocol dynamics of the TORCH trial.
Gridelli C; Butts C; Ciardiello F; Feld R; Gallo C; Perrone F
Clin Lung Cancer; 2008 Jul; 9(4):235-8. PubMed ID: 18650174
[TBL] [Abstract][Full Text] [Related]
2. Quality of life analysis of TORCH, a randomized trial testing first-line erlotinib followed by second-line cisplatin/gemcitabine chemotherapy in advanced non-small-cell lung cancer.
Di Maio M; Leighl NB; Gallo C; Feld R; Ciardiello F; Butts C; Maione P; Gebbia V; Morgillo F; Wierzbicki R; Favaretto A; Alam Y; Cinieri S; Siena S; Bianco R; Riccardi F; Spatafora M; Ravaioli A; Felletti R; Fregoni V; Genestreti G; Rossi A; Mancuso G; Fasano M; Morabito A; Tsao MS; Signoriello S; Perrone F; Gridelli C
J Thorac Oncol; 2012 Dec; 7(12):1830-1844. PubMed ID: 23154555
[TBL] [Abstract][Full Text] [Related]
3. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
Gatzemeier U; Pluzanska A; Szczesna A; Kaukel E; Roubec J; De Rosa F; Milanowski J; Karnicka-Mlodkowski H; Pesek M; Serwatowski P; Ramlau R; Janaskova T; Vansteenkiste J; Strausz J; Manikhas GM; Von Pawel J
J Clin Oncol; 2007 Apr; 25(12):1545-52. PubMed ID: 17442998
[TBL] [Abstract][Full Text] [Related]
4. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial.
Gridelli C; Ciardiello F; Gallo C; Feld R; Butts C; Gebbia V; Maione P; Morgillo F; Genestreti G; Favaretto A; Leighl N; Wierzbicki R; Cinieri S; Alam Y; Siena S; Tortora G; Felletti R; Riccardi F; Mancuso G; Rossi A; Cantile F; Tsao MS; Saieg M; da Cunha Santos G; Piccirillo MC; Di Maio M; Morabito A; Perrone F
J Clin Oncol; 2012 Aug; 30(24):3002-11. PubMed ID: 22778317
[TBL] [Abstract][Full Text] [Related]
5. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of pemetrexed as second-line therapy in advanced NSCLC after either treatment-free interval or maintenance therapy with gemcitabine or erlotinib in IFCT-GFPC 05-02 phase III study.
Bylicki O; Ferlay C; Chouaid C; Lavolé A; Barlési F; Dubos C; Westeel V; Créquit J; Corre R; Vergnenègre A; Monnet I; Le Caer H; Fournel P; Vaylet F; Falchero L; Poudenx M; Linard P; Pérol D; Zalcman G; Pérol M
J Thorac Oncol; 2013 Jul; 8(7):906-14. PubMed ID: 23591160
[TBL] [Abstract][Full Text] [Related]
7. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.
Pérol M; Chouaid C; Pérol D; Barlési F; Gervais R; Westeel V; Crequit J; Léna H; Vergnenègre A; Zalcman G; Monnet I; Le Caer H; Fournel P; Falchero L; Poudenx M; Vaylet F; Ségura-Ferlay C; Devouassoux-Shisheboran M; Taron M; Milleron B
J Clin Oncol; 2012 Oct; 30(28):3516-24. PubMed ID: 22949150
[TBL] [Abstract][Full Text] [Related]
8. Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2
Zhong WZ; Chen KN; Chen C; Gu CD; Wang J; Yang XN; Mao WM; Wang Q; Qiao GB; Cheng Y; Xu L; Wang CL; Chen MW; Kang X; Yan W; Yan HH; Liao RQ; Yang JJ; Zhang XC; Zhou Q; Wu YL
J Clin Oncol; 2019 Sep; 37(25):2235-2245. PubMed ID: 31194613
[TBL] [Abstract][Full Text] [Related]
9. Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.
Wu YL; Lee JS; Thongprasert S; Yu CJ; Zhang L; Ladrera G; Srimuninnimit V; Sriuranpong V; Sandoval-Tan J; Zhu Y; Liao M; Zhou C; Pan H; Lee V; Chen YM; Sun Y; Margono B; Fuerte F; Chang GC; Seetalarom K; Wang J; Cheng A; Syahruddin E; Qian X; Ho J; Kurnianda J; Liu HE; Jin K; Truman M; Bara I; Mok T
Lancet Oncol; 2013 Jul; 14(8):777-86. PubMed ID: 23782814
[TBL] [Abstract][Full Text] [Related]
10. Randomized, placebo-controlled, phase II study of sequential erlotinib and chemotherapy as first-line treatment for advanced non-small-cell lung cancer.
Mok TS; Wu YL; Yu CJ; Zhou C; Chen YM; Zhang L; Ignacio J; Liao M; Srimuninnimit V; Boyer MJ; Chua-Tan M; Sriuranpong V; Sudoyo AW; Jin K; Johnston M; Chui W; Lee JS
J Clin Oncol; 2009 Oct; 27(30):5080-7. PubMed ID: 19738125
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib versus gemcitabine/cisplatin in Chinese patients with EGFR mutation-positive advanced non-small-cell lung cancer: Crossover extension and post-hoc analysis of the ENSURE study.
Wu YL; Zhou C; Lu S; Qin S; Pan H; Wu G; Cheng Y; Liu X; Han B; Zhu Y; Zhong Z; Huang C; Chen L; Liang H; Li E; Jiang G
Lung Cancer; 2019 Apr; 130():18-24. PubMed ID: 30885342
[TBL] [Abstract][Full Text] [Related]
12. Multicenter randomized, open-label phase II trial of sequential erlotinib and gemcitabine compared with gemcitabine monotherapy as first-line therapy in elderly or ECOG PS two patients with advanced NSCLC.
Michael M; White SC; Abdi E; Nott L; Clingan P; Zimet A; Button P; Gregory D; Solomon B; Dobrovic A; Do H; Clarke S
Asia Pac J Clin Oncol; 2015 Mar; 11(1):4-14. PubMed ID: 24575793
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
Gridelli C; Rossi A; Di Maio M; Leo S; Filipazzi V; Favaretto AG; Burgio MA; Cinieri S; Bianco R; Ciardiello F; Cavanna L; Bordonaro R; Costanzo R; Sandomenico C; Gallo C; Perrone F; Morabito A
Clin Lung Cancer; 2014 Mar; 15(2):166-70. PubMed ID: 24418693
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of erlotinib plus gemcitabine in first-line treatment of poor prognosis, advanced non-small cell lung cancer patients.
Grigorescu AC; Bala C
J BUON; 2013; 18(1):188-94. PubMed ID: 23613405
[TBL] [Abstract][Full Text] [Related]
15. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
Wu YL; Zhou C; Liam CK; Wu G; Liu X; Zhong Z; Lu S; Cheng Y; Han B; Chen L; Huang C; Qin S; Zhu Y; Pan H; Liang H; Li E; Jiang G; How SH; Fernando MCL; Zhang Y; Xia F; Zuo Y
Ann Oncol; 2015 Sep; 26(9):1883-1889. PubMed ID: 26105600
[TBL] [Abstract][Full Text] [Related]
16. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
Giaccone G; Herbst RS; Manegold C; Scagliotti G; Rosell R; Miller V; Natale RB; Schiller JH; Von Pawel J; Pluzanska A; Gatzemeier U; Grous J; Ochs JS; Averbuch SD; Wolf MK; Rennie P; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):777-84. PubMed ID: 14990632
[TBL] [Abstract][Full Text] [Related]
17. A multi-centre randomized, open-label phase II trial of continuous erlotinib plus gemcitabine or gemcitabine as first-line therapy in ECOG PS2 patients with advanced non-small cell lung cancer.
Michael M; Pavlakis N; Clingan P; De Boer R; Johnston M; Clarke S
Oncol Rep; 2012 Sep; 28(3):763-7. PubMed ID: 22710607
[TBL] [Abstract][Full Text] [Related]
18. A multicenter phase II randomized trial of gemcitabine followed by erlotinib at progression, versus the reverse sequence, in vulnerable elderly patients with advanced non small-cell lung cancer selected with a comprehensive geriatric assessment (the GFPC 0505 study).
LeCaer H; Greillier L; Corre R; Jullian H; Crequit J; Falchero L; Dujon C; Berard H; Vergnenegre A; Chouaid C;
Lung Cancer; 2012 Jul; 77(1):97-103. PubMed ID: 22405570
[TBL] [Abstract][Full Text] [Related]
19. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.
Wu YL; Zhou C; Hu CP; Feng J; Lu S; Huang Y; Li W; Hou M; Shi JH; Lee KY; Xu CR; Massey D; Kim M; Shi Y; Geater SL
Lancet Oncol; 2014 Feb; 15(2):213-22. PubMed ID: 24439929
[TBL] [Abstract][Full Text] [Related]
20. A Phase II trial of erlotinib as maintenance treatment after gemcitabine plus platinum-based chemotherapy in patients with recurrent and/or metastatic nasopharyngeal carcinoma.
You B; Le Tourneau C; Chen EX; Wang L; Jarvi A; Bharadwaj RR; Kamel-Reid S; Perez-Ordonez B; Mann V; Siu LL
Am J Clin Oncol; 2012 Jun; 35(3):255-60. PubMed ID: 21358293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
